Product References
Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes.
International journal of nanomedicine
Ma S,Gu C,Xu J,He J,Li S,Zheng H,Pang B,Wen Y,Fang Q,Liu W,Tian J
MA5-14509 was used in Western Blot, ELISA to improve the targeting capability and drug delivery of NP in a simulated in vivo milieu.
Tue Feb 22 00:00:00 EST 2022
Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes.
International journal of nanomedicine
Ma S,Gu C,Xu J,He J,Li S,Zheng H,Pang B,Wen Y,Fang Q,Liu W,Tian J
MA5-14509 was used in Western Blot, ELISA to improve the targeting capability and drug delivery of NP in a simulated in vivo milieu.
Tue Feb 22 00:00:00 EST 2022
Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes.
International journal of nanomedicine
Ma S,Gu C,Xu J,He J,Li S,Zheng H,Pang B,Wen Y,Fang Q,Liu W,Tian J
MA5-14509 was used in Western Blot, ELISA to improve the targeting capability and drug delivery of NP in a simulated in vivo milieu.
Tue Feb 22 00:00:00 EST 2022
Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance.
Clinical epigenetics
Li J,Fang K,Choppavarapu L,Yang K,Yang Y,Wang J,Cao R,Jatoi I,Jin VX
Published figure using ErbB2 (HER-2) recombinant monoclonal antibody (Product # MA5-14509) in Western Blot
Fri Sep 17 00:00:00 EDT 2021
Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy.
EJNMMI radiopharmacy and chemistry
Ku A,Kondo M,Cai Z,Meens J,Li MR,Ailles L,Reilly RM
MA5-14509 was used in Immunohistochemistry to assess the feasibility of a theranostic strategy that combines positron emission tomography (PET) with [64Cu]Cu-DOTA-panitumumab F(ab'')2 to image head and neck squamous cell carcinoma and predict the radiation equivalent doses to the tumour and normal organs from radioimmunotherapy with [177Lu]Lu-DOTA-panitumumab F(ab'')2.
Thu Aug 12 00:00:00 EDT 2021
Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy.
EJNMMI radiopharmacy and chemistry
Ku A,Kondo M,Cai Z,Meens J,Li MR,Ailles L,Reilly RM
MA5-14509 was used in Immunohistochemistry to assess the feasibility of a theranostic strategy that combines positron emission tomography (PET) with [64Cu]Cu-DOTA-panitumumab F(ab'')2 to image head and neck squamous cell carcinoma and predict the radiation equivalent doses to the tumour and normal organs from radioimmunotherapy with [177Lu]Lu-DOTA-panitumumab F(ab'')2.
Thu Aug 12 00:00:00 EDT 2021
Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
Translational oncology
Schoop H,Bregenzer A,Halske C,Behrens HM,Krüger S,Egberts JH,Röcken C
MA5-14509 was used in Immunohistochemistry to characterize the expression of the checkpoint proteins V-domain Ig suppressor of T-cell activation (VISTA), programmed cell death 1 ligand 1 (PD-L1), and programmed cell death protein-1 (PD-1) in a cohort of GCs following platinum-based neoadjuvant chemotherapy.
Sat Feb 01 00:00:00 EST 2020
Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors.
Scientific reports
Volodko N,Gutor T,Petronchak O,Huley R,Dúcka M,Šmarda J,Borsig L,Beneš P,Knopfová L
MA5-14509 was used in Immunohistochemistry to determine if c-Mby expression is associated with an increased presence of TAMs in human breast tumors.
Mon Aug 12 00:00:00 EDT 2019
Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
mAbs
Dobosz M,Haupt U,Scheuer W
MA514509 was used in immunohistochemistry - paraffin section to optimize in vivo and ex vivo fluorescence imaging for the preclinical development and characterization of therapeutic monoclonal antibodies
Sun Jan 01 00:00:00 EST 2017
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Breast cancer research and treatment
Matsumoto H,Thike AA,Li H,Yeong J,Koo SL,Dent RA,Tan PH,Iqbal J
MA514509 was used in immunohistochemistry to explore the relationship between tumor-infiltrating lymphocytes and the clinical outcomes of triple-negative breast cancers
Fri Apr 01 00:00:00 EDT 2016
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Oncology letters
Liu YX,Wang KR,Xing H,Zhai XJ,Wang LP,Wang W
MA5-14509 was used in immunohistochemistry - paraffin section to classify triple-negative breast cancer into subtypes
Mon Aug 01 00:00:00 EDT 2016
Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer.
Medicine
Chung MJ,Lee JH,Kim SH,Suh YJ,Choi HJ
MA514509 was used in immunohistochemistry - paraffin section to examine the association between pretreatment molecular and clinical factors and axillary lymph node metastases in early breast cancer
Sun May 01 00:00:00 EDT 2016
Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining.
Applied immunohistochemistry & molecular morphology : AIMM
Wang D,Pang Z,Clarke GM,Nofech-Mozes S,Liu K,Cheung AM,Filkins RJ,Yaffe MJ
MA514509 was used in immunohistochemistry - paraffin section to develop a non-cross-reactive multiplex to measure 8 common breast cancer biomarkers
Fri Jul 01 00:00:00 EDT 2016
Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Breast cancer research and treatment
Oon ML,Thike AA,Tan SY,Tan PH
MA5-14509 was used in immunohistochemistry to evaluate the presence of cancer stem cells and EMT markers as prognostic markers for breast metaplastic carcinoma
Sun Feb 01 00:00:00 EST 2015
Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
Breast cancer research and treatment
Koh VC,Lim JC,Thike AA,Cheok PY,Thu MM,Tan VK,Tan BK,Ong KW,Ho GH,Tan WJ,Tan Y,Salahuddin AS,Busmanis I,Chong AP,Iqbal J,Thilagaratnam S,Wong JS,Tan PH
MA5-14509 was used in immunohistochemistry - paraffin section to assess the clinicopathological and immunohistochemical characteristics, and the clinical outcomes, between screen-detected and symptomatic DCIS
Wed Jul 01 00:00:00 EDT 2015
Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.
Breast cancer research and treatment
Cheung SY,Boey YJ,Koh VC,Thike AA,Lim JC,Iqbal J,Tan PH
MA5-14509 was used in immunohistochemistry - paraffin section to characterize triple-negative breast cancer and the role of epithelial-mesenchymal transition markers
Sat Aug 01 00:00:00 EDT 2015
Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Breast cancer research and treatment
Savci-Heijink CD,Halfwerk H,Hooijer GK,Horlings HM,Wesseling J,van de Vijver MJ
MA5-14509 was used in immunohistochemistry - paraffin section to analyze breast cancer subtypes and retrospective analysis of metastatic behaviour
Wed Apr 01 00:00:00 EDT 2015
The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Pathology, research and practice
Kapucuoğlu N,Bozkurt KK,Başpınar Ş,Koçer M,Eroğlu HE,Akdeniz R,Akçil M
MA5-14509 was used in immunohistochemistry to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast
Thu Oct 01 00:00:00 EDT 2015
Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nigerian journal of clinical practice
Nwafor CC,Keshinro SO
MA5-14509 was used in immunohistochemistry - paraffin section to discuss how to treat the four types of breast cancer
Thu Mar 24 00:00:00 EDT 2016
A novel, automated technology for multiplex biomarker imaging and application to breast cancer.
Histopathology
Clarke GM,Zubovits JT,Shaikh KA,Wang D,Dinn SR,Corwin AD,Santamaria-Pang A,Li Q,Nofech-Mozes S,Liu K,Pang Z,Filkins RJ,Yaffe MJ
MA5-14509 was used in immunohistochemistry to develop an automated system for the multiplex image analysis of breast cancer biomarkers
Wed Jan 01 00:00:00 EST 2014
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
Lab on a chip
Galletti G,Sung MS,Vahdat LT,Shah MA,Santana SM,Altavilla G,Kirby BJ,Giannakakou P
MA5-14509 was used in immunocytochemistry and western blot to study the ability of a microfluidic device utilizing an anti-HER2 antibody to isolate circulating breast cancer and gastric cancer tumor cells
Tue Jan 07 00:00:00 EST 2014
Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.
American journal of clinical pathology
Dean SJ,Perks CM,Holly JM,Bhoo-Pathy N,Looi LM,Mohammed NA,Mun KS,Teo SH,Koobotse MO,Yip CH,Rhodes A
MA5-14509 was used in immunohistochemistry to study the relationship in triple-negative breast cancer of PTEN, IGFBP2 and clinicopathology
Sat Mar 01 00:00:00 EST 2014
Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.
Human pathology
Gulbahce HE,Vanderwerf S,Blair C,Sweeney C
MA5-14509 was used in immunohistochemistry to study the lobular inflammation observed in non-neoplastic tissue from breast cancer patients and high risk prophylactic mastectomy patients
Wed Jan 01 00:00:00 EST 2014
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
PloS one
Jackson D,Atkinson J,Guevara CI,Zhang C,Kery V,Moon SJ,Virata C,Yang P,Lowe C,Pinkstaff J,Cho H,Knudsen N,Manibusan A,Tian F,Sun Y,Lu Y,Sellers A,Jia XC,Joseph I,Anand B,Morrison K,Pereira DS,Stover D
Published figure using ErbB2 (HER-2) recombinant monoclonal antibody (Product # MA5-14509) in Immunohistochemistry
Wed Sep 17 00:00:00 EDT 2014
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
PloS one
Jackson D,Atkinson J,Guevara CI,Zhang C,Kery V,Moon SJ,Virata C,Yang P,Lowe C,Pinkstaff J,Cho H,Knudsen N,Manibusan A,Tian F,Sun Y,Lu Y,Sellers A,Jia XC,Joseph I,Anand B,Morrison K,Pereira DS,Stover D
Published figure using ErbB2 (HER-2) recombinant monoclonal antibody (Product # MA5-14509) in Immunohistochemistry
Wed Sep 17 00:00:00 EDT 2014
The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.
Annals of oncology : official journal of the European Society for Medical Oncology
Prins MJ,Ruurda JP,van Diest PJ,van Hillegersberg R,Ten Kate FJ
MA5-14509 was used in immunohistochemistry to study the prognostic value of HER2 expression and gene amplification in esophageal adenocarcinoma
Wed May 01 00:00:00 EDT 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Cancer research
Zhang X,Claerhout S,Prat A,Dobrolecki LE,Petrovic I,Lai Q,Landis MD,Wiechmann L,Schiff R,Giuliano M,Wong H,Fuqua SW,Contreras A,Gutierrez C,Huang J,Mao S,Pavlick AC,Froehlich AM,Wu MF,Tsimelzon A,Hilsenbeck SG,Chen ES,Zuloaga P,Shaw CA,Rimawi MF,Perou CM,Mills GB,Chang JC,Lewis MT
MA5-14509 was used in immunohistochemistry to establish a panel of biologically diverse and phenotypically stable transplantable cell lines from patient tissues for use in xenograft models of breast cancer
Thu Aug 01 00:00:00 EDT 2013
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer.
Cellular oncology (Dordrecht)
Vlug EJ,van de Ven RA,Vermeulen JF,Bult P,van Diest PJ,Derksen PW
MA5-14509 was used in immunohistochemistry - paraffin section to review the contribution of Yes Associated Protein to various types of cancer
Tue Oct 01 00:00:00 EDT 2013
Trastuzumab for the treatment of salivary duct carcinoma.
The oncologist
Limaye SA,Posner MR,Krane JF,Fonfria M,Lorch JH,Dillon DA,Shreenivas AV,Tishler RB,Haddad RI
MA5-14509 was used in immunohistochemistry to study the efficacy of trastuzumab therapy in salivary duct carcinoma and the clinical value of HER2 testing
Mon Sep 30 00:00:00 EDT 2013
False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Journal of clinical pathology
Nunes CB,Rocha RM,Buzelin MA,Balabram D,de Souza Foureaux F,Porto SS,Gobbi H
MA5-14509 was used in immunohistochemistry to use DDISH to study the sensitivity and specificity of a panel of five anti-HER2 antibodies against invasive breast cancer tissue microarray samples
Fri Nov 01 00:00:00 EDT 2013
SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients.
Journal of clinical pathology
D'Alfonso TM,Liu YF,Chen Z,Chen YB,Cimino-Mathews A,Shin SJ
MA5-14509 was used in immunohistochemistry to compare the utility of the SP3 rabbit monoclonal antibody and the HercepTest for the determination of breast cancer patient HER2/neu status
Wed May 01 00:00:00 EDT 2013
Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Human pathology
Gulbahce HE,Sweeney C,Surowiecka M,Knapp D,Varghese L,Blair CK
MA5-14509 was used in immunohistochemistry to study the clinical significance of GAT-3 expression in breast cancer patients receiving either systemic chemotherapy or hormone therapy
Fri Nov 01 00:00:00 EDT 2013
Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas.
Journal of breast cancer
Do SI,Kim K,Kim DH,Chae SW,Park YL,Park CH,Sohn JH
MA5-14509 was used in immunohistochemistry to study the clinical and prognostic significance of the expression of MUC1, MUC2, MUC5AC and MUC6 in human breast ductal carcinomas
Sat Jun 01 00:00:00 EDT 2013
Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.
Clinics (Sao Paulo, Brazil)
Aguiar FN,Mendes HN,Cirqueira CS,Bacchi CE,Carvalho FM
MA5-14509 was used in immunohistochemistry - paraffin section to learn about a new potential marker for low risk of invasion in ductal carcinoma in situ is called basal cytokeratin
Wed May 01 00:00:00 EDT 2013
Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology.
Diagnostic cytopathology
van Hemel BM,Suurmeijer AJ
MA5-14509 was used in immunocytochemistry to study the feasibility of performing cytopathological, immunohistochemical and molecular biological analyses on samples prepared using a combination of PreservCytª and Cellientª technologies
Thu Aug 01 00:00:00 EDT 2013
Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.
PloS one
Vermeulen JF,Kornegoor R,van der Wall E,van der Groep P,van Diest PJ
MA5-14509 was used in immunohistochemistry to compare the expression of growth factor receptors and membrane-bound tumor markers in male and female breast cancer
Tue Jul 02 00:00:00 EDT 2013
Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer.
PloS one
Kuijpers CC,Moelans CB,van Slooten HJ,Horstman A,Hinrichs JW,Al-Janabi S,van Diest PJ,Jiwa M
MA5-14509 was used in immunohistochemistry to study the value of using MLPA and CISH to determine HER2 status in patients with invasive breast cancer
Thu Sep 11 00:00:00 EDT 2014
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.
Breast cancer research : BCR
Dekker TJ,Borg ST,Hooijer GK,Meijer SL,Wesseling J,Boers JE,Schuuring E,Bart J,van Gorp J,Mesker WE,Kroep JR,Smit VT,van de Vijver MJ
MA5-14509 was used in immunohistochemistry to study a tissue micro-array approach for monitoring the sensitivity and specificity of HER2 measurements in breast cancer
Wed Jun 13 00:00:00 EDT 2012
The 3-layered ductal epithelium in gynecomastia.
The American journal of surgical pathology
Kornegoor R,Verschuur-Maes AH,Buerger H,van Diest PJ
MA5-14509 was used in immunohistochemistry to perform an immunohistochemical characterization of gynecomastia
Tue May 01 00:00:00 EDT 2012
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.
The oncologist
Macfarlane R,Seal M,Speers C,Woods R,Masoudi H,Aparicio S,Chia SK
MA5-14509 was used in immunohistochemistry to study changes in biomarker expression between primary breast cancer and relapsed metastatic tumors using paired tissue microarray analysis
Mon Jun 25 00:00:00 EDT 2012
Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer.
Molecular carcinogenesis
Naushad SM,Pavani A,Rupasree Y,Divyya S,Deepti S,Digumarti RR,Gottumukkala SR,Prayaga A,Kutala VK
MA5-14509 was used in immunohistochemistry to investigate one-carbon metabolism dysfunction in breast cancer progression
Mon Oct 01 00:00:00 EDT 2012
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Breast cancer research and treatment
Allison KH,Kandalaft PL,Sitlani CM,Dintzis SM,Gown AM
MA5-14509 was used in immunohistochemistry to study whether standard pathological parameters are predictive of Oncotype DX scores in a subset of estrogen receptor-positive breast cancer patients
Sun Jan 01 00:00:00 EST 2012
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Breast cancer research and treatment
Joosse SA,Brandwijk KI,Devilee P,Wesseling J,Hogervorst FB,Verhoef S,Nederlof PM
MA5-14509 was used in immunohistochemistry to develop a method to predict BRCA2-association in hereditary breast carcinomas
Sun Apr 01 00:00:00 EDT 2012
Cell cycle proteins predict recurrence in stage II and III colon cancer.
Annals of surgical oncology
Belt EJ,Brosens RP,Delis-van Diemen PM,Bril H,Tijssen M,van Essen DF,Heymans MW,Beliën JA,Stockmann HB,Meijer S,Meijer GA
MA5-14509 was used in immunohistochemistry to study the prognostic value of the immunohistochemical expression of various cell cycle proteins in patients with stage II and stage III colon cancer
Sun Jul 01 00:00:00 EDT 2012
14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.
FEBS letters
Zheng G,Xiong Y,Yi S,Zhang W,Peng B,Zhang Q,He Z
MA5-14509 was used in western blot to investigate the involvement of 14-3-3 delta in the chemotherapeutic sensitivity of MCF-7 cells
Fri Jan 20 00:00:00 EST 2012
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.
Experimental and therapeutic medicine
Rau KM,Huang CC,Chiu TJ,Chen YY,Lu CC,Liu CT,Pei SN,Wei YC
MA5-14509 was used in immunohistochemistry to study the prognostic value of CD105 expression in breast cancers
Wed Aug 01 00:00:00 EDT 2012
Increased FDG uptake in breast cancer is associated with prognostic factors.
Annals of nuclear medicine
Sanli Y,Kuyumcu S,Ozkan ZG,Işik G,Karanlik H,Guzelbey B,Turkmen C,Ozel S,Yavuz E,Mudun A
MA5-14509 was used in immunohistochemistry to study the relationship between FDG uptake and prognostic factors in breast cancer
Tue May 01 00:00:00 EDT 2012
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Cancer letters
Barok M,Tanner M,Köninki K,Isola J
MA5-14509 was used in immunohistochemistry to investigate the efficacy of Trastuzumab-DM1 for the treatment of gastric cancer expressing HER2
Thu Jul 28 00:00:00 EDT 2011
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
Breast cancer research : BCR
Teng YH,Tan WJ,Thike AA,Cheok PY,Tse GM,Wong NS,Yip GW,Bay BH,Tan PH
MA5-14509 was used in immunohistochemistry - paraffin section to study EGFR gene in triple negative breast cancer and its therapeutic application
Fri Apr 01 00:00:00 EDT 2011
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Histopathology
Boers JE,Meeuwissen H,Methorst N
MA5-14509 was used in immunohistochemistry to study HER2 status in gastro-oesophageal adenocarcinomas using rabbit monoclonal antibodies and FISH/SISH
Tue Feb 01 00:00:00 EST 2011
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
Cellular oncology (Dordrecht)
Heerma van Voss MR,van der Groep P,Bart J,van der Wall E,van Diest PJ
MA5-14509 was used in immunohistochemistry to study the expression of the stem cell marker ALDH1 in BRCA1 related breast cancer
Tue Feb 01 00:00:00 EST 2011
The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells.
Breast cancer research and treatment
Shi M,Liu D,Duan H,Qian L,Wang L,Niu L,Zhang H,Yong Z,Gong Z,Song L,Yu M,Hu M,Xia Q,Shen B,Guo N
MA5-14509 was used in western blot to study a beta2-adrenergic receptor-Her2 positive feedback loop and its role in human breast cancer
Sat Jan 01 00:00:00 EST 2011
HER2/neu revisited: quality and interpretive issues.
Journal of clinical pathology
Ahmed SS,Iqbal J,Thike AA,Lim AS,Lim TH,Tien SL,Tan PH
MA5-14509 was used in immunohistochemistry to perform a retrospective analysis of the concordance of IHC and FISH testing of HER2/neu status
Tue Feb 01 00:00:00 EST 2011
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Genes, chromosomes & cancer
Joosse SA,Brandwijk KI,Mulder L,Wesseling J,Hannemann J,Nederlof PM
MA5-14509 was used in immunohistochemistry to study the genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors
Tue Feb 01 00:00:00 EST 2011
Molecular phenotypes of matched in situ and invasive components of breast carcinomas.
Human pathology
Martins D,Sousa B,Lopes N,Gomes M,Veronese L,Albergaria A,Paredes J,Schmitt F
MA5-14509 was used in immunohistochemistry to compare the tissue microarray immunoprofiles of in situ and invasive breast carcinoma components within the same sample
Sat Oct 01 00:00:00 EDT 2011
Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
Japanese journal of clinical oncology
Lee DS,Kim SH,Suh YJ,Kim S,Kim HK,Shim BY
MA5-14509 was used in immunohistochemistry to investigate the possible prognostic value of p53 overexpression in breast cancer patients
Fri Jul 01 00:00:00 EDT 2011
The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.
International journal of medical sciences
Atahan K,Küpeli H,Gür S,Yiğitbaşı T,Baskın Y,Yiğit S,Deniz M,Cökmez A,Tarcan E
MA5-14509 was used in immunohistochemistry to investigate the diagnostic values of Bc1, Bc2 and Bc3 in early breast cancer
Sat Feb 12 00:00:00 EST 2011
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Annals of oncology : official journal of the European Society for Medical Oncology
Bueno-de-Mesquita JM,Nuyten DS,Wesseling J,van Tinteren H,Linn SC,van de Vijver MJ
MA5-14509 was used in immunohistochemistry to study the significance of inter-observer variation in pathological assessment of node-negative breast cancer
Fri Jan 01 00:00:00 EST 2010
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Thike AA,Cheok PY,Jara-Lazaro AR,Tan B,Tan P,Tan PH
MA5-14509 was used in immunohistochemistry to investigate the clinicopathological characteristics of triple-negative breast cancer and its relationship with basal-like breast cancer
Fri Jan 01 00:00:00 EST 2010
Clinicopathological significance of calreticulin in breast invasive ductal carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Lwin ZM,Guo C,Salim A,Yip GW,Chew FT,Nan J,Thike AA,Tan PH,Bay BH
MA5-14509 was used in immunohistochemistry to investigate the prognostic significance of calreticulin in advanced tumors
Wed Dec 01 00:00:00 EST 2010
The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.
Cancer
Tan YO,Han S,Lu YS,Yip CH,Sunpaweravong P,Jeong J,Caguioa PB,Aggarwal S,Yeoh EM,Moon H
MA5-14509 was used in immunohistochemistry to perform a literature survey of ErbB2-positive breast cancer in Asia
Wed Dec 01 00:00:00 EST 2010
The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
American journal of clinical pathology
Rhodes A,Sarson J,Assam EE,Dean SJ,Cribb EC,Parker A
MA5-14509 was used in immunohistochemistry to investigate the reliability of rabbit monoclonal antibody immunohistochemical testing
Fri Oct 01 00:00:00 EDT 2010
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Breast cancer research and treatment
Liu S,Chia SK,Mehl E,Leung S,Rajput A,Cheang MC,Nielsen TO
MA5-14509 was used in immunohistochemistry to study the prognostic value of the progesterone receptor in adjuvant tamoxifen therapy of breast cancer
Fri Jan 01 00:00:00 EST 2010
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Breast cancer research and treatment
Freedman OC,Amir E,Hanna W,Kahn H,O'Malley F,Dranitsaris G,Cole DE,Verma S,Folkerd E,Dowsett M,Clemons M
MA5-14509 was used in immunohistochemistry to study the therapeutic benefit of exemestane and anastrozole treatment in post-menopausal women with hormone receptor-positive breast cancer
Fri Jan 01 00:00:00 EST 2010
Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
The Malaysian journal of pathology
Bong PN,Zakaria Z,Muhammad R,Abdullah N,Ibrahim N,Emran NA,Syed Hussain SN
MA5-14509 was used in immunohistochemistry to investigate GATA3 mutations and expression in Malaysian breast tumors
Wed Dec 01 00:00:00 EST 2010
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
BMC cancer
Holstege H,van Beers E,Velds A,Liu X,Joosse SA,Klarenbeek S,Schut E,Kerkhoven R,Klijn CN,Wessels LF,Nederlof PM,Jonkers J
MA5-14509 was used in immunohistochemistry to evaluate array comparative genomic hybridization data from murine and human BRCA1 and BRCA2 breast cancers
Tue Aug 24 00:00:00 EDT 2010
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.
BMC cancer
Lee CM,Tannock IF
MA5-14509 was used in immunohistochemistry to study the immunohistochemical distribution of cetuximab and trastuzumab within human tumor xenografts
Thu Jun 03 00:00:00 EDT 2010
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
BMC cancer
Tan MH,Wong CF,Tan HL,Yang XJ,Ditlev J,Matsuda D,Khoo SK,Sugimura J,Fujioka T,Furge KA,Kort E,Giraud S,Ferlicot S,Vielh P,Amsellem-Ouazana D,Debré B,Flam T,Thiounn N,Zerbib M,Benoît G,Droupy S,Molinié V,Vieillefond A,Tan PH,Richard S,Teh BT
MA5-14509 was used in immunohistochemistry to identify genetic differences between two closely related carcinomas
Wed May 12 00:00:00 EDT 2010
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.
Breast cancer research : BCR
Behbod F,Kittrell FS,LaMarca H,Edwards D,Kerbawy S,Heestand JC,Young E,Mukhopadhyay P,Yeh HW,Allred DC,Hu M,Polyak K,Rosen JM,Medina D
MA5-14509 was used in immunocytochemistry to develop an in vivo model for noninvasive breast tumors
Tue Mar 02 00:00:00 EST 2010
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Breast cancer research : BCR
Sassen A,Diermeier-Daucher S,Sieben M,Ortmann O,Hofstaedter F,Schwarz S,Brockhoff G
MA5-14509 was used in immunohistochemistry to investigate the mechanism for cellular susceptibility to Herceptin
Wed Feb 24 00:00:00 EST 2010
Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles.
Histopathology
Lopes N,Sousa B,Vieira D,Milanezi F,Schmitt F
MA5-14509 was used in immunohistochemistry to study the microvessel features in subtype of breast carcinomas
Sun Nov 01 00:00:00 EDT 2009
An improved processing method for breast whole-mount serial sections for three-dimensional histopathology imaging.
American journal of clinical pathology
Sun L,Wang D,Zubovits JT,Yaffe MJ,Clarke GM
MA5-14509 was used in immunohistochemistry to evaluate a novel processing method for breast whole-mount histopathology imaging
Sun Mar 01 00:00:00 EST 2009
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Breast cancer research and treatment
Joosse SA,van Beers EH,Tielen IH,Horlings H,Peterse JL,Hoogerbrugge N,Ligtenberg MJ,Wessels LF,Axwijk P,Verhoef S,Hogervorst FB,Nederlof PM
MA5-14509 was used in immunohistochemistry to study the role of BRCA1 in hereditary non-BRCA1/2 breast carcinomas
Sat Aug 01 00:00:00 EDT 2009
Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study.
Genes, chromosomes & cancer
Wang C,Iakovlev VV,Wong V,Leung S,Warren K,Iakovleva G,Arneson NC,Pintilie M,Miller N,Youngson B,McCready DR,Done SJ
MA5-14509 was used in immunohistochemistry to compare the genomic changes between primary breast cancer and their metastases
Tue Dec 01 00:00:00 EST 2009
RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Pathology, research and practice
Tezel GG,Uner A,Yildiz I,Guler G,Takahashi M
MA5-14509 was used in immunohistochemistry to investigate the expression of RET finger protein in patients with breast carcinoma
Tue Aug 18 00:00:00 EDT 2009
Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Boone J,van Hillegersberg R,Offerhaus GJ,van Diest PJ,Borel Rinkes IH,Ten Kate FJ
MA5-14509 was used in immunohistochemistry to study current targets for molecular therapy in esophageal squamous cell carcinoma
Tue Nov 24 00:00:00 EST 2009
Toker cells revisited.
The breast journal
Nofech-Mozes S,Hanna W
MA5-14509 was used in immunohistochemistry to examine the Toker cells in nipples without Paget disease in mastectomy specimens
Tue Nov 03 00:00:00 EST 2009
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
BMC cancer
Wang L,Jiang Z,Sui M,Shen J,Xu C,Fan W
MA5-14509 was used in immunohistochemistry to evaluate potential biomarkers for the selection of breast cancer treatment regimens
Sat Jul 11 00:00:00 EDT 2009
Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
Diagnostic cytopathology
Hanley KZ,Siddiqui MT,Lawson D,Cohen C,Nassar A
MA5-14509 was used in immunohistochemistry to evaluate multiple monoclonal antibodies for breast cancer studies
Wed Apr 01 00:00:00 EDT 2009
Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.
BMC cancer
Rosa FE,Silveira SM,Silveira CG,Bérgamo NA,Neto FA,Domingues MA,Soares FA,Caldeira JR,Rogatto SR
MA5-14509 was used in immunohistochemistry to evaluate the methods to detect HER-2 detection in tumors
Mon Mar 23 00:00:00 EDT 2009
Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Asian Pacific journal of cancer prevention : APJCP
Munjal K,Ambaye A,Evans MF,Mitchell J,Nandedkar S,Cooper K
MA5-14509 was used in immunohistochemistry to characterize the relationship between breast cancer immunohistochemistry and prognosis
Thu May 13 00:00:00 EDT 2010
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
Revista da Associacao Medica Brasileira (1992)
Rocha RM,Nunes CB,Sanches FS,Rocha GF,Oliveira FN,Reis-Filho JS,Lambros MB,Gobbi H
MA5-14509 was used in immunohistochemistry to evaluate novel rabbit monoclonal antibodies for estrogen, progesterone receptors and HER2
Thu May 06 00:00:00 EDT 2010
Cytological criteria to predict basal phenotype of breast carcinomas.
Diagnostic cytopathology
Dufloth RM,Alves JM,Martins D,Vieira DS,Chikota H,Zeferino LC,Schmitt F
MA5-14509 was used in immunohistochemistry to investigate the phenotypic classification of breast cancer based on cytological criteria
Sun Nov 01 00:00:00 EDT 2009
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Chia S,Norris B,Speers C,Cheang M,Gilks B,Gown AM,Huntsman D,Olivotto IA,Nielsen TO,Gelmon K
MA5-14509 was used in immunohistochemistry to investigate the usefulness of HER2 for the prognosis of specific breast tumors
Wed Dec 10 00:00:00 EST 2008
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Clinical cancer research : an official journal of the American Association for Cancer Research
Cheang MC,Voduc D,Bajdik C,Leung S,McKinney S,Chia SK,Perou CM,Nielsen TO
MA5-14509 was used in immunohistochemistry to define the prognostic markers of basal-like breast cancer
Sat Mar 01 00:00:00 EST 2008
Clinical validation of a customized multiple signature microarray for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Tan BK,Tan LK,Yu K,Tan PH,Lee M,Sii LH,Wong CY,Ho GH,Yeo AW,Chow PK,Koong HN,Yong WS,Lim DT,Ooi LL,Soo KC,Tan P
MA5-14509 was used in immunohistochemistry to develop a customized microarray for the clinical classification of breast tumors
Tue Jan 15 00:00:00 EST 2008
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
Breast cancer research : BCR
Crabb SJ,Bajdik CD,Leung S,Speers CH,Kennecke H,Huntsman DG,Gelmon KA
MA5-14509 was used in immunohistochemistry to identify prognostic biomarkers for breast cancer involving 4 or more auxilliary lymph nodes
Wed Jun 11 00:00:00 EDT 2008
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Breast cancer research : BCR
Jensen MR,Schoepfer J,Radimerski T,Massey A,Guy CT,Brueggen J,Quadt C,Buckler A,Cozens R,Drysdale MJ,Garcia-Echeverria C,Chène P
MA5-14509 was used in immunohistochemistry to examine the therapeutic potential of HSP90 inhibitor NVP-AUY922 in breast cancer treatment
Mon Jul 21 00:00:00 EDT 2008
Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease.
Histopathology
Kim TH,Huh JH,Lee S,Kang H,Kim GI,An HJ
MA5-14509 was used in immunohistochemistry to study the role of CLDN2 expression in breast cancer development and progression
Tue Jul 01 00:00:00 EDT 2008
Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
American journal of clinical pathology
van Dekken H,Hop WC,Tilanus HW,Haringsma J,van der Valk H,Wink JC,Vissers KJ
MA5-14509 was used in immunohistochemistry to evaluate tumor cell markers during malignant development in Barrett esophagus
Sat Nov 01 00:00:00 EDT 2008
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.
Breast cancer research and treatment
Rajput AB,Turbin DA,Cheang MC,Voduc DK,Leung S,Gelmon KA,Gilks CB,Huntsman DG
MA5-14509 was used in immunohistochemistry to study the presence of stromal mast cells as a favourable prognostic marker in invasive breast cancer
Tue Jan 01 00:00:00 EST 2008
Parafibromin expression in breast cancer: a novel marker for prognostication?
Journal of clinical pathology
Selvarajan S,Sii LH,Lee A,Yip G,Bay BH,Tan MH,Teh BT,Tan PH
MA5-14509 was used in immunohistochemistry to investigate the usefulness of parafibromin on breast tumor prognosis
Tue Jan 01 00:00:00 EST 2008
The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry.
Archives of pathology & laboratory medicine
Wong SC,Chan JK,Lo ES,Chan AK,Wong MC,Chan CM,Lam MY,Chan AT
MA5-14509 was used in immunohistochemistry to evaluate novel immunohistochemistry reagents and techniques
Sun Jul 01 00:00:00 EDT 2007
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Journal of clinical pathology
Ricardo SA,Milanezi F,Carvalho ST,Leitão DR,Schmitt FC
Published figure using ErbB2 (HER-2) recombinant monoclonal antibody (Product # MA5-14509) in Immunohistochemistry
Sat Sep 01 00:00:00 EDT 2007
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Journal of clinical pathology
Ricardo SA,Milanezi F,Carvalho ST,Leitão DR,Schmitt FC
Published figure using ErbB2 (HER-2) recombinant monoclonal antibody (Product # MA5-14509) in Immunohistochemistry
Sat Sep 01 00:00:00 EDT 2007
Prognostic factors in Hungarian breast cancer patients.
Anticancer research
Nádasi E,Anga B,Sándor J,Megyesi J,Kelemen D,Mottolese M,Natali PG,Hegedus G,Arany I,Ember I
MA5-14509 was used in immunohistochemistry to study potential prognostic markers in Hungarian breast cancer patients
Thu Mar 29 00:00:00 EDT 2007
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
The breast journal
Short SM,Yoder BJ,Tarr SM,Prescott NL,Laniauskas S,Coleman KA,Downs-Kelly E,Pettay JD,Choueiri TK,Crowe JP,Tubbs RR,Budd TG,Hicks DG
MA5-14509 was used in immunohistochemistry to investigate the association between paxillin expression and HER2 expression in breast cancer patients
Tue Apr 17 00:00:00 EDT 2007
Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls.
Histopathology
Ho BC,Tan HW,Lee VK,Tan PH
MA5-14509 was used in immunohistochemistry to study pitfalls in the preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast
Fri Dec 01 00:00:00 EST 2006
